Zerlasiran

N/A

Report date: 2023/05/10 16:40:49
NME

Base Information

Drug NameZerlasiran
Drug Alias NameSLN-360
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionApolipoprotein A-I inhibitorsRNA interference
TargetsApolipoprotein A-I
Therapy Area/IndicationsHyperlipidemiasDyslipidemiasLipid Metabolism Disorders +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSlovakia +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSilence Therapeutics Plc
China Registration ClassN/A

Develop Information

Active CompaniesSilence Therapeutics Plc
Inactive CompaniesN/A
Active IndicationsHyperlipidemiasDyslipidemiasLipid Metabolism Disorders +[4] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A